Some take-away points from @BarbaraPistill2 ‘s dicussion of the anti-HER2 ADCs abstracts
🔹Trials with 3 ADCs with the same target, linker & payload class
🔹In TALENT, the low pCR rate is comparable to NACT and other ADCs in HR+/ HER2- EBC
@myESMO #ESMOAmbassadors
#ESMO26
1/2
449 views · 8 likes · 5 reposts · 1 reply
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org- Philippe Aftimos, MD @aftimosp
🔹 Move towards the development and implementation of quantitative assessment of targets 🔹 Future clinical trial designs incorporating biomarker testing in early breast cancer and investigating sequential strategies in MBC @myESMO #ESMOAmbassadors #ESMO26 2/2
Source: Philippe Aftimos, MD · x.com